Abstract
BRCA1 and BRCA2 mutation carriers have elevated risks of breast and ovarian cancers. The risks for cancers at other sites remain unclear. Melanoma has been associated with BRCA2 mutations in some studies, however, few surveys have included non-melanoma skin cancer. We followed 2729 women with a BRCA1 or BRCA2 mutation for an average of 5.0 years. These women were asked to report new cases of cancer diagnosed in themselves or in their family. The risks of skin cancer were compared for probands with BRCA1 and BRCA2 mutations. Of 1779 women with a BRCA1 mutation, 29 developed skin cancer in the follow-up period (1.6%). Of the 950 women with a BRCA2 mutation, 28 developed skin cancer (3.0%) (OR = 1.83 for BRCA2 versus BRCA1; 95% CI 1.08–3.10; P = 0.02). The odds ratio for basal cell carcinoma was higher (OR = 3.8; 95% CI 1.5–9.4; P = 0.002). BRCA2 mutation carriers are at increased risk for skin cancer, compared with BRCA1 carriers, in particular for basal cell carcinoma.
Similar content being viewed by others
References
Ford D, Easton D, Bishop T, Narod S et al (1994) Risk of cancer in BRCA1 mutation carriers. Lancet 343:692–695
The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316
Thompson D, Easton DF (2002) Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365
Brose M, Rebbeck T, Calzone K et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a cancer risk evaluation program. J Natl Cancer Inst 94:1365–1372
Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H (1999) Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germ-line mutation carriers. Eur J Cancer 35:1248–1257
Bermejo JL, Hemminki K (2004) Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol 15:1834–1841
Shih H, Nathanson K, Seal S, Collins N, Stratton M, Rebbeck T, Weber B (2000) BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6:4259–4264
Easton D, Steele L, Fields P, Ormiston W et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on Chromosome 13q12–13. Am J Hum Genet 61:120–128
Moslehi R, Chu W, Karlan B et al (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66:1259–1272
Risch H, McLaughlin J, Cole D, Rosen B et al (2001) Prevalence of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710
Aretini P, D’ Andrea E, Pasini B, Viel A et al (2003) Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat 81:71–79
Streuwing J, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408
Goldgar DE, Easton DF, Cannon-Albright L, Skolnick M (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600–1608
Berman D, Costalas J, Schultz D, Grana G, Daly M, Godwin A (1996) A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish and non-Jewish individuals. Cancer Res 56:3409–3414
Hahn S, Greenhalf B, Ellis I, Sina-Frey M et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221
Murphy K, Brune K, Griffin C, Sollenberger J et al (2002) Evaluation of candidate genes MPP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789–3793
Lal G, Liu G, Schmocker B et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1 and BRCA2 mutations. Cancer Res 60:409–416
Kirchhoff T, Kauff N, Mitra N et al (2004) BRCA mutations and the risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10:2918–2921
Edwards SM, Kote-Jarai Z, Meitz J et al (2003) Two percent of men with early onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1–12
Vazina A, Baniel J, Shtriker A et al (2000) The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 83:463–466
Hubert A, Peretz T, Manor O et al (1999) The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65:921–924
Thorlacius S, Struewing J, Hartge P et al (1998) Population based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352:1337–1339
Sigurdsson S, Thorlaciaus S, Tomasson J et al (1997) BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75:758–761
Iscovich J, Abdulrazik M, Cour C et al (2002) Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. Int J Cancer 98:42–44
Scott R, Vajdic C, Armstrong B et al (2002) BRCA2 mutations in a population based series of patients with ocular melanoma. Int J Cancer 102:188–191
Niell B, Rennert G, Bonner J, Almog R, Tomsho L, Gruber S (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96:15–21
Kirchhoff T, Satagopan J, Kauff N et al (2004) Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 96:68–70
Chen-Stoyerman R, Figer A, Fidder H et al (2001) The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. Br J Cancer 84:475–477
Drucker L, Stackievitz R, Shpitz B, Yarkoni S (2000) Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. Anticancer Res 20:559–561
Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94:1221–1226
Amos CR (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:74–75
Risch H, Narod S (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:73–74
Pharoah PP, Antoniou A, Hopper J, Easton D (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:75–76
Whittemore AS, Gong G (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:76–77
Burke W, Austin MA (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:78–79
Easton DF, Hopper JL, Thomas DL, Antoniou A, Pharoah PDP, Whittemore AS (2004) Re: breast cancer risks for BRCA1/2 carriers. Science 306:2187–2188
Wacholder S, Struewing JP, Hartage P, Greene MH, Tucker MA (2004) Re: breast cancer risks for BRCA1/2 carriers. Science 306:2188
King MC, New York Breast Cancer Study Group (2004) Re: breast cancer risks for BRCA1/2 carriers. Science 306:2188–2191
Offit K (2006) BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 98(23):1675–1677
Easton DR, Ford D, Bishop DT (1995) Breast and ovarian incidence in BRCA1-mutartion carriers. Am J Hum Genet 56:256–271
Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H (2003) Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 5:R175–R186
Miller DL, Weinstock MA (1994) Nonmelanoma skin cancer in the United States: incidence. J Am Acad Derm 30:774–778
SEER 17 (2000–2006). http://seer.cancer.gov
Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 carriers: minireview. British J Cancer 96:11–15
Iscovitch J, Abdulrazik M, Cour C et al (2002) Prevalence of the BRCA2 6174delT mutation in uveal melanoma patients. Int J Cancer 98:42–44
Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, Lotem M (2009) Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 8:29–32
Monerrat C, Chompret A, Kannengiesser C, Avril M-F et al (2007) BRCA1, BRCA2, CDKN2a germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer 6:453–461
Navaraj A, Mori T, El-Deiry WS (2005) Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biol Ther 4:1409–1414
Acknowledgments
We thank David Livingston for helpful discussion. We thank Marcia Llaquachaqui, Anna Tulman and Adriana Valentini for data review and processing. Funded by the Canadian Breast Cancer Research Alliance.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Other members of the Hereditary Breast Cancer Clinical Study Group: Olufunmilayo I Olopade, Nadine Tung, Fergus Couch, Barry Rosen, Eitan Friedman, Andrea Eisen, Susan Domchek, Dominique Stoppa-Lyonnet, Ruth Gershoni-Baruch, David Horsman, Teresa Wagner, Howard Saal, Wendy Meschino, Kenneth Offit, Amber Trivedi, Mark Robson, Michael Osborne, Dawna Gilchrist, Charis Eng, Jeffrey Weitzel, Wendy McKinnon, Marie Wood, Barbara Pasini, Peter Ainsworth, Mary Daly, Judy Garber, Kevin Sweet, Taya Fallen, Beth Karlan, Raluca Kurz, Claudine Isaacs, Susan Neuhausen, Siranoush Manoukian, Susan Armel, Rochelle Demsky, Edmond Lemire, Jane Mclennan, Gareth Evans.
Rights and permissions
About this article
Cite this article
Ginsburg, O.M., Kim-Sing, C., Foulkes, W.D. et al. BRCA1 and BRCA2 families and the risk of skin cancer. Familial Cancer 9, 489–493 (2010). https://doi.org/10.1007/s10689-010-9377-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-010-9377-y